Topics

RedHill Biopharma Announces Full Results from Phase 3 Study and Supportive Top-Line Results from Open-Label Extension Study with RHB-104 in Crohn’s Disease

10:19 EDT 11 Oct 2019 | Speciality Pharma Journal

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 11, 2019 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced  full Week 52 results for all subjects in the previously announced …

Original Article: RedHill Biopharma Announces Full Results from Phase 3 Study and Supportive Top-Line Results from Open-Label Extension Study with RHB-104 in Crohn’s Disease

NEXT ARTICLE

More From BioPortfolio on "RedHill Biopharma Announces Full Results from Phase 3 Study and Supportive Top-Line Results from Open-Label Extension Study with RHB-104 in Crohn’s Disease"

Quick Search

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...